opdivogastroeso.com domain details, Adjuvant and Metastatic Gastroesophageal Cancers | OPDIVO® (nivolumab) and OPDIVO + FOLFOX or CapeOX
Description: OPDIVO® (nivolumab), alone or in combination, is approved in UGI cancers in both the adjuvant and 1L metastatic setting. Please see Indications and Important Safety Information.
Domain rank: 492914
Indexed URLs from opdivogastroeso.com website (10)
The links in column here only counts links from external domains.
found date
links in
url title
url
2022-07-18
Checkmate 649 Efficacy Data | OPDIVO® (nivolumab) + FOLFOX or CapeOX
2022-07-18
OPDIVO® (nivolumab) Efficacy Data for the Adjuvant Treatment of ESO and GEJ Cancers
2022-08-31
OPDIVO® (nivolumab) + Chemo Efficacy Data for Gastroesophageal Cancers
2022-08-31
Adjuvant and Metastatic Gastroesophageal Cancers | OPDIVO® (nivolumab) and OPDIVO + FOLFOX or CapeOX
2023-01-04
2023-01-04
2022-09-12
OPDIVO® (nivolumab) + Chemo Efficacy Data for Gastroesophageal Cancers
2022-06-26
Adjuvant and Metastatic Gastroesophageal Cancers | OPDIVO® (nivolumab) and OPDIVO + FOLFOX or CapeOX
2023-01-04
OPDIVO® (nivolumab) Efficacy Data for the Adjuvant Treatment of Urothelial Carcinoma
2023-01-04